“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.
In this video, Ronald Swerdloff, MD, discusses the takeaways of the study, “Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men,” presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Swerdloff is a professor of medicine and senior investigator at The Lundquist Institute, Harbor-UCLA Medical Center and David Geffen School of Medicine, University of California, Los Angeles.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.